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Abstract
            Atrial fibrillation could be induced reproducibly by 50Hz rapid stimulation which was 
given through systolic and early diastolic phase of atrial excitation. Duration of atrial fibrillation 
induced in this way was roughly dependent on the current amplitude of the stimulation. The 
minimum current that could induce long-lasting atrial fibrillation (30sec in the clinical setting, 
2sec in the rabbit or rat model) was defined as atrial fibrillation threshold (AFT). AFT was larger 
in patients who had history of atrial fibrillation than those who did not. Anti-arrhythmic drugs 
raised AFT by various degrees both in experimental and clinical cases. Long-term efficacy of a 
drug could be predicted in a patient, measuring how much the drug increased AFT (cut-off point 
= 5mA increase). AFT is a useful marker to evaluate atrial vulnerability and to guide 
pharmacological treatment of atrial fibrillation.
Introduction
            Atrial fibrillation is a target of intensive research because fibrillation is the final frontier 
in the arrhythmology1  ,2  ,3  . Now we have several therapeutic modalities for this common 
arrhythmia, including pharmacological and non-pharmacological approach. However, long-term 
success rate of these treatments would be 50% to 60 % at the best 4 . There are several reasons 
for its difficulty: 1)this arrhythmia is essentially due to aging in clinical cases, 2)the mechanism 
of this arrhythmia is not fully understood5 , 3)there is no appropriate animal model6 . We have 
been working on these problems for several years, and become to use atrial fibrillation threshold 
as a tool to evaluate the easiness to induce atrial fibrillation (atrial vulnerability) both in the 
experimental7 ,8 ,9 ,10 and the clinical11 ,12 ,13 settings. This is the unique parameter to evaluate 
atrial vulnerability quantitatively12 ,13 . Because very few researches have been done in this field, 
I will summarize the data from our laboratory, comparing with the ventricular counterpart in this 
review article.
What is fibrillation threshold ?                                                                                       
         Fibrillation threshold has been studied mostly in the ventricle14-16 since Wiggers et al17 ,18 . 
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A single stimulus was given to induce ventricular fibrillation in the diseased and the normal 
hearts. For this purpose, the stimulus should be given at a critical time point with sufficient 
current amplitude. The time point is usually located at around the peak of T wave of ECG. The 
minimum current amplitude to induce fibrillation is defined as fibrillation threshold. This 
concept is based on a fact that fibrillation can be induced by larger current than a critical 
(threshold) amplitude. Recently, it is recognized that the second critical amplitude exists when 
current amplitude is increased incrementally. Larger current than the second critical point can not 
induce fibrillation, but rather terminate fibrillation  19  ,20  . This point is called defibrillation 
threshold, which is now widely studied because of implantable cardioverter defibrillators in 
clinical use. In the combination with vulnerable period (the zone of the critical time points to 
induce fibrillation), there is an area in the strength-interval curve where fibrillation can be 
induced by a single stimulus 17 ,18 . This area is shifted rightwards along the axis of coupling 
interval, for example, when myocardial ischemia or anti-arrhythmic drugs are introduced  21 
(Figure 1). The same argument could be applied to the atrium. However, atrial vulnerable period 
was less defined than that of the ventricle 22 ,23 . Atrial T wave is barely discernable in a standard 
ECG.
 
Figure 1: Strength-interval relations in provoking fibrillation: Figure shows an 
example of strength-interval relations. Triangles are pacing threshold at each 
coupling interval after an initial deflection of atrial/ventricular activity. Circles 
indicate   induction   of   repetitive   responses,   and   squares   show   induction   of 
fibrillation. Closed symbols are control data and open symbols are data obtained 
in the presence of ischemia or procainamide.
            There have been several methods to induce ventricular fibrillation 14 ,17 . Among them, a 
continuous high frequency pacing at 50-100Hz which covers a whole “vulnerable period” can 
induce fibrillation consistently 14 . Thus we applied this type of stimulation to the atrium and the 
minimum current to induce long-lasting atrial fibrillation (>30sec in clinical settings, >2sec in 
experiments) was defined as fibrillation threshold (Figure 2). Duration of “long-lasting” atrial 
fibrillation was selected rather arbitrarily as the definition but it was based on the relationship 
between the current intensity and the duration (see Matsuo et al9 ). The duration was positively 
correlated with the current intensity until the current reached the threshold. This definition is 
different from conventional usage in terms of the stimulating pattern. 
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Figure 2: Measurement of atrial fibrillation threshold: Three leads of a standard 
ECG record and 3 intra-cardiac records are shown. HRA, RAA and CS are high 
right atrium, right atrial appendage and coronary sinus, respectively. In the middle 
of the figure, a rapid pacing at 50Hz was applied to HRA for 1sec, which was 
induced atrial fibrillation. A constant pacing at a rate of 120/min preceded a rapid 
pacing. Duration of atrial fibrillation was measured, and then current amplitude of 
the rapid pacing was increased for the next trial. The minimum current that could 
induce “sustained” fibrillation was defined as atrial fibrillation threshold.
Mechanism of induction of fibrillation                                                  . 
            The precise mechanism of induction of fibrillation by a single pulse or train pulses is not 
clear. However, there are some observational studies in the ventricle14 ,15 ,17 ,19 : 1) localized 
repetitive activities were induced at the stimulating site, 2) excitations were propagated, 3) 
repetitive excitations were observed at many sites of the myocardium 4)excitations resulted in 
disorganized activity (fibrillation) because of inhomogeneity of conduction and repolarization. 
When high frequency stimulation is given to the ventricle at an intensity of diastolic threshold, 
ventricular response mimicking ventricular tachycardia could be observed. As the intensity is 
raised incrementally, the intervals of ventricular excitation become shorter. At and beyond a 
critical intensity of the stimulating current, ventricular excitations become fibrillation. Although 
these results are based on the ventricular study, it is probable that the same phenomenon could be 
observed in the atrium. 
Experimental methodology of induction of atrial fibrillation                                                     . 
            Most popular method to induce atrial fibrillation would be an extra-stimulus method, that 
is, an extra-stimulus is given to the atrium at a critical time point after basic conditioning 
stimulations at a fixed rate 23 . Because reproducibility of this method is relatively low, statistical 
evaluation is often necessary after many trials 24 to evaluate drug efficacy or atrial vulnerability. 
On the other hand, continuous rapid pacing could easily induce fibrillation. Thus this method 
was introduced for the quantitative evaluation of atrial vulnerability (easiness to induce atrial 
fibrillation). We chose 50Hz for 1sec stimulation for this purpose. The increment of the current 
intensity is 1mA for the clinical setting, and 0.1 to 0.5mA for the experimental use.  
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Experimental results                                                                                                     . 
            Atrial fibrillation threshold has been measured in the isolated hearts of guinea pig or 
rabbit.   Sodium  channel  blockers7  ,8  ,11  (disopyramide,   pilsicainide,   flecainide,   aprindine, 
lidocaine), potassium channel blockers7 ,10 (E-4031), amiodarone, and SD-32129 raised atrial 
fibrillation threshold by various degrees. Although the increase of atrial fibrillation threshold 
induced by anti-arrhythmic drugs was positively related to the increase of effective refractory 
period, E-4031 had the least potency 7 . This results could be explained by the fact that sodium 
channel blockers made refractory period longer than E-4031 did because of longer post-
excitation refractoriness after a high frequency stimulation 25 . Note that the blocking effect of 
potassium channels by Ikr blockers (such as E-4031) is less prominent when the excitation 
frequency becomes higher (reverse use-dependent block26  , but see Ohler et al27  ). In the 
presence of anti-arrhythmic drugs in the perfusing solution, it was more difficult to induce 
repetitive atrial firing or atrial fibrillation by electrical stimulation. At the same time, atrial 
fibrillation threshold was increased.                                                               . 
            Effective refractory period becomes shorter when a rapid pacing is continuously applied 
to the atrium. This phenomenon is called “atrial electrical remodeling” 28 , which is accompanied 
by the reduction of L-type calcium current and transient outward current2 ,29 . Expression of 
novel channels was also reported  30  . Large numbers of experimental studies have been 
performed regarding atrial remodeling. In these studies, single extra-stimulus or burst pacing 
similar to ours has been used to induce atrial fibrillation. However, atrial vulnerability was 
compared in terms of the duration of atrial fibrillation that was induced, but not the intensity of 
the stimulation. These studies did not evaluate how easy to induce atrial fibrillation, but how 
difficult to recover from the arrhythmia. The evaluation of the duration of the arrhythmia 
disclose its stability after the physiological and the biochemical changes of the atrium were 
implemented, but it could not be suitable to evaluate the propensity of the patients to paroxysmal 
attack of atrial fibrillation. In our experience, a stronger current to the atrium could induce longer 
atrial fibrillation until the current reached the fibrillation threshold12 . 
Clinical feasibility
            Experimental data suggested that the measurement of the threshold could predict the 
easiness to induce atrial fibrillation. Indeed atrial fibrillation threshold was lower in the patients 
who had a history of atrial fibrillation (median 11mA) than normal control (median 5mA)12 . 
When cut-off point was set at 10mA, the sensitivity and the specificity were 94%, and 60%, 
respectively.   Effective   refractory   period,   conduction   time,   or   other   indicators   of   atrial 
vulnerability were not different between two groups. The secondary indicators to distinguish the 
patients with atrial fibrillation from normal subjects were %maximum atrial fragmentation 
(%MAF) and fragmented activity zone (FAZ)31 . Their sensitivity and specificity were 78%, 
52% (%MAF), and 47%, 84% (FAZ), respectively. %MAF is the relative increase of the width 
of local atrial electrogram by the extra-stimulation. FAZ is the zone of coupling intervals that 
made local atrial electrogram longer by 50% or more.                                          
             Atrial fibrillation threshold (AFT) could be affected by the autonomic tone because 
isoproterenol infusion decreased AFT (unpublished data). The data obtained on the day when the 
catheters were inserted were lower than those obtained on the following days. Thus the results of 
the measurement should be interpreted cautiously. However, reproducibility of AFT was 
excellent (±1mA, r=0.95 on the regression line) during a short term examination (<3 hours), or if 
it was measured on the next day or later after the catheters were inserted.
Evaluation of drug efficacy in the clinical setting                                                                        
       The benefit of the AFT measurement would be quantitative evaluation of the drug efficacy. 
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Anti-arrhythmic drugs raised AFT in general, but the increase of AFT by a drug was different in 
the individual patient. For example, procainamide raised AFT by 5mA in a patient, but 
propafenone did not change AFT at all in the same patient. In this way, we could categorize anti-
arrhythmic drugs into 2 groups in the individual patient, i.e. drugs that raise AFT significantly, 
and drugs that does not increase AFT in the patient. The effective drugs in a patient were not 
necessarily the same in another patient. When the cut-off point of effectiveness was set to 5mA 
increase, “effective” drug could prevent 88% of the patients from the recurrence of atrial 
fibrillation at least for 1 year whereas only 13% were free from atrial fibrillation with 
“ineffective” drugs13 . Thus this method could be used to select effective drugs in an individual 
patient. However, the prediction of the effectiveness did not mean the high efficacy of the drug 
in a large population. As previously reported1,4, efficacy of each drug against atrial fibrillation 
was around 40 to 50% in our study. AFT is a method to select beneficial drugs to the specific 
patient. Serial electrophysiological test has been less recommended in case of ventricular 
tachycardia, because “effective drug” determined in terms of inducibility did not improve the 
prognosis of the patients  32  . On the other hand, AFT does not depend on all-or-none type 
determination of inducibility, but it determines how strong is the drug effect against the 
arrhythmia. As a matter of fact, atrial fibrillation was always induced in this method because of 
the definition of AFT.
Rate control and rhythm control                                                                                                   
           Clearly, AFT measurement determines a drug suitable to maintain sinus rhythm. Recently, 
the results of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) 
study were published33 . This study did not show the advantage of maintaining sinus rhythm over 
heart rate control in terms of prognosis. This result may argue against the usefulness of AFT 
measurement.   However,   mortality   of   the   patients   who   suffered   from   paroxysmal   atrial 
fibrillation is relatively low. The biggest concern of the patients is often its symptom. Thus, 
when mortality is not different, it would be desirable to select less symptomatic life. In this 
sense, pharmacological treatment with class I anti-arrhythmic drugs could still be a first line 
therapy for “lone” atrial fibrillation.
AFT in the future                                                                                                                            
           AFT is a quantitative marker to select effective drugs against atrial fibrillation. The 
concept of this method is “custom-made” medicine. Large-scale population study would reveal 
overall efficacy of the drug, but a negative side is negligence of individuality or specificity of 
each patient. Because the efficacy of pharmacological and non-pharmacological treatment is still 
not high, it is important to know which method should be applied first. It is possible to measure 
AFT first, and if “effective” drug could be found, the patient should be treated with the regimen. 
If “effective” drug is not found, catheter ablation or some other non-pharmacological approach 
should be considered.
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